



## **Angiochem Appoints Executive Chairman and Elects New Board of Directors**

**MONTREAL, QUEBEC -- (Marketwired - April 28, 2016 )** - Angiochem, a biotechnology company developing peptide drug conjugates uniquely capable of crossing the blood-brain barrier, has appointed Mr. John Huss as Executive Chairman and elected a new board of directors. The company also announced the closing of a private financing led by a syndicate of family offices and angels as well as existing investor BDC Capital.

“Angiochem’s compounds have the potential to address significant unmet needs. As such, I am honored and excited to be part of Angiochem as we work to further develop treatments for a range of diseases, including leptomenigeal carcinomatosis,” said John Huss, newly appointed Executive Chairman. “As a result of the financing, Angiochem is sufficiently funded to pursue its strategic objectives. I would also like to formally welcome the Board of Directors,” he added.

John Huss has more than 25 years of global pharmaceutical experience. He spent 20 years with Merck & Co., Roche and Sanofi on the pharmaceutical side of the business, before moving to biotechnology. He served as CEO, President and Director of Theratechnologies and is currently Founder, President and CEO of H&P Labs Inc. He is also Vice-President, member of the Executive Committee and a Director at BioQuebec.

The following board members were elected at Angiochem’s Annual General Meeting in Montreal on April 12th:

**Jean-François Pariseau** is Partner in the Healthcare Fund at BDC Capital. He has over 20 years of investment and entrepreneurial experience in the healthcare sector and has invested and managed more than \$200 million in biopharmaceutical and medical device companies in North America. His experience includes IPOs, M&A and fund investment transactions in private

and public companies. Mr. Pariseau also currently sits on the Board of Directors of Clementia Pharmaceuticals, Profound Medical (TSXV:PRN), Imagia Cybernetics and Clearwater Clinical.

**Sena K. Biswas** is Managing Director, Life Sciences at VIMAC, one of the most active U.S. Venture firms in Canada. Mr. Biswas has served as Founding CEO and President of several life science companies, most recently at Merrimack Pharmaceuticals. Representing VIMAC, Mr. Biswas also serves on the board of directors for Neotropix, Inc.

**Robert Blain**, with more than 20 years in the international entertainment industry, is Co-CEO of Groupe Lune Rouge Inc., a company that develops projects and invests in different funds with a focus on Technology, Life sciences, Entertainment and Real Estate. As well as taking care of the Family office of Mr. Guy Laliberté, Mr. Blain also acts as an investment manager in Lune Rouge. Since 2007, Mr. Blain has been an administrator and treasurer for One Drop Foundation which aims to fight poverty by supporting access to water worldwide. He also sits as the Treasurer on Sainte-Justine UHC Foundation, one of the most important pediatric centers in North America.

**Martin Godbout** has held numerous executive positions over the past 25 years, including as President & CEO, of Innovatech Quebec, Executive Vice-President of BioCapital and President & CEO of Genome Canada. Mr. Godbout is currently Chairman of the Board of AmorChem, BioContact, BIOQuébec, Génome Québec, and is a Board member of Chelation Partners, Fonds de recherche du Québec - Santé, The Leukodystrophies Foundation and Foundation of Ataxia Charlevoix-Saguenay. Mr. Godbout is an Officer of the Order of Canada.

### **About Angiochem**

Angiochem is a clinical-stage biotechnology company discovering and developing new breakthrough peptide drug conjugates that leverage the LRP-1 mediated pathway to cross the BBB to treat neurological diseases. These new compounds have the potential to address significant medical needs, many of which are insurmountable due to the fundamental physiological challenge posed by the BBB.

Angiochem is developing a focused product pipeline, including small molecules and biologics, for the potential treatment of a wide range of CNS diseases, including primary brain cancer, brain metastases, lysosomal storage diseases and pain. Founded in 2003, Angiochem maintains headquarters in Montreal, Canada. For additional information about the Company, please visit <http://www.angiochem.com>.

**For more information, please contact:**

Mr. John Huss  
Executive Chairman  
514-591-7991  
jhuss@angiochem.com

Crystal Quast  
Bullseye Corporate  
647-529-6364  
Quast@BullseyeCorporate.com